Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HQL and 80,000+ other tickers.
See exactly how HQL's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HQL and 80,000+ other tickers.
Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and…
I maintain a buy rating on abrdn Life Sciences Investors Fund (HQL), which trades at an 8.49% discount to NAV and offers a 12.6% yield. HQL is positioned to benefit from the accelerating GLP-1 market, with top holdings in high-growth biotech names and a portfolio heavily weighted to biotechnology. While total returns have been competitive, HQL's high distributions come at the expense of capital appreciation, making it best suited for income-focused investors.
PHILADELPHIA, May 11, 2026 /PRNewswire/ -- The following Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on May 29, 2026 to all shareholders of record as of May 21, 2026 (ex-dividend date May 21, 2026). The abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), and the India Fund, Inc. (IFN) will pay their distributions on June 30, 2026, to shareholders of record as of May 21, 2026 (ex‑dividend date May 21, 2026).
The market environment is challenging, to say the least. We discuss how one should invest in today's market. The article presents five different investment strategies, including a fixed-income strategy, high-income strategy, sleep-well-at-night strategy, growth-focused strategy, and the Near-Perfect Portfolio strategy. Selecting a strategy aligned with personal risk tolerance and sticking to it through cycles is critical for long-term success.
PHILADELPHIA, March 31, 2026 /PRNewswire/ -- The Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF) (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on March 31, 2026, on a per share basis to all shareholders of record as of March 24, 2026 (ex-dividend date March 24, 2026). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and Aberdeen India Fund Inc. (IFN) which paid on March 31, 2026, to all shareholders of record as of February 20, 2026 (ex-dividend date February 20, 2026).
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% plus yield and 10.8% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.